Results 11 to 20 of about 3,679,356 (272)

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients [PDF]

Frontiers in Pharmacology
Introduction:Current clinical research has reported the effectiveness and safety of venetoclax in combination with hypomethylating agents (VEN-HMA) in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
Ludan Zhang, Rui Ge, Deng Pan, Pengjie Yue, Jingwen Zhang, Renjie Bian, Xiaojing Yan   +6 more
doaj   +2 more sources

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. [PDF]

Cancer
Abstract Background In younger, fit patients with acute myeloid leukemia (AML), intensive chemotherapy (IC) followed by consolidation or allogeneic hematopoietic stem cell transplantation (HSCT) is the standard approach. The authors performed a systematic review and meta‐analysis to evaluate younger patients with AML treated with hypomethylating agents
Perrone S, De Fazio L, Monachetti S, Molica M.   +3 more
europepmc   +2 more sources

Immunological effects of hypomethylating agents [PDF]

Expert Review of Hematology, 2017
Epigenetic changes resulting from aberrant methylation patterns are a recurrent observation in hematologic malignancies. Hypomethylating agents have a well-established role in the management of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.
Katherine E. Lindblad, Meghali Goswami, Christopher S. Hourigan, Karolyn A. Oetjen   +3 more
openaire   +2 more sources

Clinical update on hypomethylating agents [PDF]

International Journal of Hematology, 2019
Hypomethylating agents (HMAs), azacitidine and decitabine, are standards of care in higher-risk myelodysplastic syndromes and in acute myeloid leukemia patients ineligible for intensive therapy. Over the last 10 years, research efforts have sought to better understand their mechanism of action, both at the molecular and cellular level.
Matthieu, Duchmann, Raphael, Itzykson
openaire   +2 more sources

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology, 2023
Background Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
N. Short, M. Muftuoglu, F. Ong, L. Nasr, W. Macaron, G. Montalban-Bravo, Y. Alvarado, Mahesh Basyal, N. Daver, C. Dinardo, G. Borthakur, N. Jain, M. Ohanian, E. Jabbour, G. Issa, W. Qiao, Xuelin Huang, R. Kanagal-Shamanna, K. Patel, P. Bose, F. Ravandi, R. Delumpa, R. Abramova, G. Garcia-Manero, M. Andreeff, J. Cortes, H. Kantarjian   +26 more
semanticscholar   +1 more source

AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Cancer, 2023
Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia.
E. Todisco, C. Papayannidis, N. Fracchiolla, E. Petracci, C. Zingaretti, C. Vetro, M. Martelli, P. Zappasodi, N. Di Renzo, Susanna Gallo, E. Audisio, D. Griguolo, C. Cerchione, C. Selleri, D. Mattei, M. Bernardi, M. Fumagalli, Giuliana Rizzuto, L. Facchini, C. Basilico, Ilenia Manfra, E. Borlenghi, R. Cairoli, P. Salutari, M. Gottardi, A. Molteni, V. Martini, M. Lunghi, L. Fianchi, D. Cilloni, F. Lanza, E. Abruzzese, N. Cascavilla, F. Rivellini, F. Ferrara, L. Maurillo, J. Nanni, A. Romano, V. Cardinali, F. Gigli, E. Roncoroni, V. Federico, G. Marconi, R. Volpi, M. Sciumè, C. Tarella, G. Rossi, Giovanni Martinelli   +47 more
semanticscholar   +1 more source

Mitoxantrone—A Hypomethylating Agent? [PDF]

Cancer Biology & Therapy, 2003
Commentary to: Mitoxantrone Mediates Demethylation and Re-Expression of Cyclin D2, Estrogen Receptor 14.3.3 Sigma In Breast Cancer Cells Belinda S. Parker, Suzanne M. Cutts, Abraham Nudelman, Ada Rephaeli, Don R.
Allen S. Yang, Jean-Pierre J. Issa
openaire   +1 more source

Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies

Cancers, 2023
Simple Summary The association of venetoclax (VEN) with hypomethylating agents (HMAs) such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of patients with newly diagnosed acute myeloid leukemia (AML) who are not eligible ...
A. Ucciero, F. Pagnoni, L. Scotti, Alessia Pisterna, Francesco Barone-Adesi, Gianluca Gaidano, A. Patriarca, M. Lunghi   +7 more
semanticscholar   +1 more source

Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

British Journal of Haematology, 2023
Venetoclax (VEN) is an FDA‐approved selective inhibitor of B‐cell leukaemia/lymphoma‐2 (BCL‐2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (
Ahmad Nanaa, R. He, J. Foran, T. Badar, N. Gangat, A. Pardanani, W. Hogan, M. Litzow, M. Patnaik, A. Al-Kali, H. Alkhateeb   +10 more
semanticscholar   +1 more source

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Blood Advances, 2023
Key Points • The mPRS can accurately segregate 3 groups of patients with AML with different outcomes with HMA and Ven.• Patients with FLT3-ITD and NRAS/KRAS mutations have a relatively unfavorable outcome with HMA and Ven, for which new strategies are ...
A. Bataller, A. Bazinet, C. Dinardo, A. Maiti, G. Borthakur, N. Daver, N. Short, E. Jabbour, G. Issa, N. Pemmaraju, M. Yilmaz, G. Montalban-Bravo, Koichi Takahashi, S. Loghavi, G. Garcia-Manero, F. Ravandi, H. Kantarjian, T. Kadia   +17 more
semanticscholar   +1 more source